Our Pricing

Understanding Saxenda Tablets and Oral Weight Loss Alternatives in the UK

Published: 23 August 2026

Many patients searching for saxenda tablets are looking for oral alternatives to the traditional Saxenda injection pen. While Saxenda (liraglutide) is currently only licensed in the UK as a subcutaneous injection, several effective oral weight loss tablets are now available through UK pharmacies, offering comparable clinical outcomes for patients who prefer tablet formulations. Understanding the differences between injectable and oral weight loss medications helps patients make informed decisions with their prescriber.

Why Saxenda Tablets Are Not Currently Available in the UK

Patients frequently ask about saxenda tablets because oral medications offer convenience advantages over daily injections. However, Saxenda (liraglutide 6mg/ml) is currently licensed by the MHRA exclusively as a subcutaneous injection administered via pre-filled pen [1]. The molecular structure of liraglutide makes oral absorption challenging, as the peptide would be broken down by digestive enzymes before reaching systemic circulation.

Pharmaceutical manufacturers have invested significant research into developing oral GLP-1 receptor agonists that overcome these absorption barriers. The breakthrough came with semaglutide, the same active ingredient found in Wegovy injections, which has been successfully formulated as an oral tablet with absorption-enhancing technology [2]. This represents the first orally available GLP-1 medication for weight management in the UK.

Oral Alternatives to Saxenda Tablets: Wegovy Pill and Other Options

For patients seeking tablet alternatives to saxenda tablets, Wegovy Oral Tablets (semaglutide pill) provide the most comparable option within the same medication class. Clinical trials demonstrated that oral semaglutide produces average weight loss of 15.1% of initial body weight over 68 weeks, compared to 2.4% with placebo [2]. The tablet formulation uses an absorption enhancer called SNAC, allowing the medication to pass through the stomach lining before digestive breakdown occurs.

Wegovy Oral Tablets are available at Cured Pharmacy from £63.00, subject to prescriber approval following a free online consultation. The treatment requires once-daily administration on an empty stomach, with specific timing requirements to optimise absorption. Our UK-registered clinical team, led by superintendent pharmacist Tarun Kumar (GPhC 2233073), assesses each patient's suitability during the consultation process.

How Oral Semaglutide Compares to Injectable Saxenda

Both medications belong to the GLP-1 receptor agonist class and work through similar mechanisms—reducing appetite, slowing gastric emptying, and improving glycaemic control. The STEP 8 trial directly compared injectable semaglutide 2.4mg weekly against liraglutide 3mg daily, showing semaglutide produced significantly greater weight reduction (15.8% vs 6.4% at 68 weeks) [3]. While this study used injectable formulations, the oral semaglutide tablet delivers equivalent systemic exposure to the weekly injection when taken daily at appropriate doses.

Other Tablet Options Beyond Saxenda Tablets for Weight Management

Patients who cannot access saxenda tablets have several evidence-based oral weight loss medications available through UK pharmacies. Orlistat 120mg capsules represent the most established option, working through a completely different mechanism by blocking approximately 30% of dietary fat absorption [4]. This treatment is available from £63.00 at Cured Pharmacy and does not require the same injection technique training as GLP-1 medications.

Mysimba tablets offer another oral alternative, combining naltrexone and bupropion to reduce food cravings and appetite through central nervous system pathways. Clinical trials showed average weight loss of 8.1% versus 4.9% with placebo over 56 weeks in patients without diabetes [5]. Each medication requires individual assessment by a UK prescriber to determine suitability based on medical history, current medications, and weight loss goals.

Clinical Evidence for Saxenda Tablets Versus Current Injectable Formulation

The SCALE clinical trial programme established liraglutide 3mg daily injection as an effective weight management medication, with participants achieving average weight loss of 8.4kg (9.2% of initial weight) compared to 2.8kg (3.2%) with placebo over 56 weeks [1]. These results apply specifically to the subcutaneous injection formulation currently marketed as Saxenda, as oral liraglutide formulations have not progressed to regulatory approval for weight management indications.

Research into oral delivery systems for peptide medications continues, with several pharmaceutical companies investigating alternative formulations. Until such products receive MHRA licensing, patients seeking saxenda tablets in the UK should consider the proven oral alternatives already available, particularly Wegovy Oral Tablets which offer superior weight loss outcomes within the same medication class [2].

Understanding GLP-1 Medication Absorption Challenges

GLP-1 receptor agonists are peptide-based medications with molecular structures vulnerable to enzymatic degradation in the gastrointestinal tract. This biological barrier prevented oral formulations until pharmaceutical advances enabled protective delivery systems. The SNAC absorption enhancer used in oral semaglutide temporarily increases stomach pH and enhances paracellular absorption, allowing the medication to reach systemic circulation before breakdown occurs [2]. This technology represents a significant advancement but requires strict administration protocols—tablets must be taken on an empty stomach with minimal water, followed by a 30-minute fasting period.

Purchasing Saxenda Tablets and Oral Weight Loss Medications Through Cured Pharmacy

While saxenda tablets are not currently available, Cured Pharmacy offers the full range of MHRA-licensed oral weight loss medications at competitive UK pricing. Our transparent pricing model displays costs upfront, before the consultation process begins—Wegovy Oral Tablets from £63.00, Orlistat from £63.00, and Mysimba from £63.00. All prescription medications require completion of a free online clinical assessment, typically taking under 3 minutes, reviewed by our UK-registered prescribers.

Our service includes discreet packaging, next-day delivery options, and ongoing clinical support throughout your treatment journey. As a GPhC-registered pharmacy (9012511), we dispense only genuine UK-licensed medications sourced through regulated supply chains. Patients receive the same pharmaceutical-grade products available through high-street pharmacies, with the added convenience of online consultation and home delivery. New customers Save £20 on their first order using code Weightlossnew, making evidence-based weight management more accessible.

What to Expect When Switching from Saxenda Tablets Search to Oral Alternatives

Patients initially searching for saxenda tablets often find that oral semaglutide or other tablet options better suit their preferences and lifestyle. The transition from considering injectable Saxenda to starting an oral weight loss medication involves consultation with a UK prescriber who will assess your BMI, medical history, previous weight loss attempts, and any contraindications. Our clinical team considers factors including cardiovascular risk profile, diabetes status, and concurrent medications when recommending the most appropriate treatment [6].

Oral weight loss medications require commitment to lifestyle modifications alongside pharmacotherapy. Clinical trials demonstrating significant weight loss outcomes all included reduced-calorie diets and increased physical activity as part of the intervention [1][2][4]. Our prescribers provide guidance on evidence-based dietary approaches and realistic weight loss expectations during the consultation process. Most patients begin seeing measurable weight reduction within 12-16 weeks of starting treatment, with maximum effects typically observed after 6-12 months of consistent use combined with behaviour modifications.

Common Side Effects of Oral Weight Loss Tablets

Gastrointestinal symptoms represent the most frequently reported side effects across all oral weight loss medication classes. GLP-1 receptor agonists like oral semaglutide commonly cause nausea, diarrhoea, constipation, and abdominal discomfort, particularly during dose escalation phases [2]. Orlistat produces different side effects related to its fat-blocking mechanism, including oily stools, faecal urgency, and flatulence, especially when consuming high-fat meals [4]. Most adverse effects diminish over time as the body adapts to treatment. Patients experiencing persistent or severe symptoms should contact their prescriber for dose adjustment or alternative medication consideration.

Scientific References

1. Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., ... & Wilding, J. P. (2015). A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine, 373(1), 11-22. [accessed 23 August 2026]
2. Rubino, D. M., Greenway, F. L., Khalid, U., O'Neil, P. M., Rosenstock, J., Sørrig, R., ... & Wilding, J. P. (2022). Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial. JAMA, 327(2), 138-150. [accessed 23 August 2026]
3. Rubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., ... & Sjöström, C. D. (2021). Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA, 325(14), 1414-1425. [accessed 23 August 2026]
4. Torgerson, J. S., Hauptman, J., Boldrin, M. N., & Sjöström, L. (2004). XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care, 27(1), 155-161. [accessed 23 August 2026]
5. Greenway, F. L., Fujioka, K., Plodkowski, R. A., Mudaliar, S., Guttadauria, M., Erickson, J., ... & COR-I Study Group. (2010). Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet, 376(9741), 595-605. [accessed 23 August 2026]
6. National Institute for Health and Care Excellence. (2023). Obesity: identification, assessment and management (CG189). NICE guideline. [accessed 23 August 2026]
7. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 23 August 2026.
8. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 23 August 2026.
9. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 23 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.